Acadia Pharmaceuticals Inc.’s Nuplazid (pimavanserin) has failed to show an effect on the primary endpoint in a Phase III trial for the adjuvant treatment of refractory schizophrenia, but the compound showed promise against negative symptoms which may be confirmed in an ongoing Phase II of the drug, currently marketed for hallucinations and delusions in Parkinson’s disease psychosis.
“Based upon today's top line results, we do not plan to initiate further clinical development of pimavanserin for an inadequate...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)